Literature DB >> 25736054

Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan: An Epidemiological Study Based on a National Administrative Database.

Atsuhiko Murata1, Kohji Okamoto2, Toshihiko Mayumi3, Keiji Muramatsu4, Shinya Matsuda4.   

Abstract

This study investigated the time trends and hospital factors affecting the use of drugs for infectious disease-associated disseminated intravascular coagulation (DIC) based on a national administrative database. A total of 14 324 patients with infectious disease-associated DIC were referred to 1041 hospitals from 2010 to 2012 in Japan. Patients' data were collected from the administrative database to determine time trends and hospital factors affecting the use of drugs for DIC. Three study periods were established, namely, the fiscal years 2010 (n = 3308), 2011 (n = 5403), and 2012 (n = 5613). The use of antithrombin, heparin, protease inhibitors, and recombinant human soluble thrombomodulin (rhs-TM) for DIC was evaluated. The frequency of use of antithrombin, heparin, and protease inhibitors decreased while that of rhs-TM significantly increased from 2010 to 2012 in Japan (25.1% in 2010, 43.1% in 2011, and 56.8% in 2012; P < .001, respectively). Logistic regression showed that the study period was associated with the use of rhs-TM in patients with DIC. The odds ratio (OR) for 2011 was 2.34 (95% confidence interval [CI], 2.12-2.58; P < .001) whereas that for 2012 was 4.34 (95% CI, 3.94-4.79; P < .001). A large hospital size was the most significant factor associated with the use of rhs-TM in patients with DIC (OR, 3.14; 95% CI, 2.68-3.66; P < .001). The use of rhs-TM has dramatically increased. A large hospital size was significantly associated with the increased use of rhs-TM in patients with DIC from 2010 to 2012 in Japan.
© The Author(s) 2015.

Entities:  

Keywords:  administrative database; disseminated intravascular coagulation; hospital factors; recombinant human soluble thrombomodulin; time trend

Mesh:

Substances:

Year:  2015        PMID: 25736054     DOI: 10.1177/1076029615575072

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  8 in total

Review 1.  Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan.

Authors:  Toshiaki Iba; Jecko Thachil
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

2.  Time Trends of the Outcomes and Treatment Options for Disseminated Intravascular Coagulation: A Nationwide Observational Study in Japan.

Authors:  Kazuma Yamakawa; Hiroyuki Ohbe; Kohei Taniguchi; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  JMA J       Date:  2020-09-23

Review 3.  Sepsis and disseminated intravascular coagulation.

Authors:  Kohji Okamoto; Toshihisa Tamura; Yusuke Sawatsubashi
Journal:  J Intensive Care       Date:  2016-03-23

4.  Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.

Authors:  Akiyoshi Hagiwara; Noriko Tanaka; Tatsuki Uemura; Wataru Matsuda; Akio Kimura
Journal:  BMJ Open       Date:  2016-12-30       Impact factor: 2.692

Review 5.  A summary of the Japan septic disseminated intravascular coagulation study.

Authors:  Mineji Hayakawa; Kota Ono
Journal:  Acute Med Surg       Date:  2018-01-10

6.  Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation.

Authors:  Toshiaki Iba; Akiyoshi Hagiwara; Daizoh Saitoh; Hideaki Anan; Yutaka Ueki; Koichi Sato; Satoshi Gando
Journal:  Ann Intensive Care       Date:  2017-11-02       Impact factor: 6.925

7.  Nationwide registry of sepsis patients in Japan focused on disseminated intravascular coagulation 2011-2013.

Authors:  Mineji Hayakawa; Kazuma Yamakawa; Shinjiro Saito; Shigehiko Uchino; Daisuke Kudo; Yusuke Iizuka; Masamitsu Sanui; Kohei Takimoto; Toshihiko Mayumi
Journal:  Sci Data       Date:  2018-12-11       Impact factor: 6.444

Review 8.  Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments.

Authors:  Mineji Hayakawa
Journal:  Open Access Emerg Med       Date:  2017-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.